The EGFR-MET bispecific antibody amivantamab in addition to the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib has shown favorable results as first-line treatment compared to osimertinib in the ongoing randomized, double-blind, phase III MARIPOSA trial. A total of 1,074 patients from 27 countries with advanced non–small-cell lung cancer (NSCLC) and activating EGFR mutations were enrolled in the study.
WCLC 2024 - Pascale Tomasini Pascale Tomasini discusses ...
WCLC 2024 - Andrea R. Filippi Andrea R. Filippi talks ...
EHA 2024 - Nitin Jain Nitin Jain elucidates the promisi ...
EHA 2024 - Umberto Vitolo Umberto Vitolo discusses eme ...
EHA 2024 - Consuelo Bertossi Consuelo Bertossi explain ...
EHA 2024 - Clemens Wendtner Clemens Wendtner provides i ...
EHA 2024 - Talha Munir Talha Munir overviews the perfor ...
EHA 2024 - Chan Cheah Chan Cheah discusses key aspects ...
A recent meta-analysis by Hwang et al. provided a comprehensive comparison of adverse event (AE) profiles of zanubrutinib with acalabrutinib in patients with B-cell malignancies. Specific AEs seen more commonly with acalabrutinib than zanubrutinib included infections, atrial fibrillation, diarrhea, nausea/vomiting, headaches, cough, fatigue and pyrexia. On the other hand, hematuria, neutropenia, and hypertension were observed more frequently with zanubrutinib than with acalabrutinib [1].
